Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 72

1.

Comparison of the immunogenicity of intramuscular versus subcutaneous administration of trivalent inactivated influenza vaccine in individuals with neuromuscular diseases.

Golekoh MC, Hu S, Norman AM, Horn PS, Brady RC, Wong BL.

J Child Neurol. 2013 May;28(5):596-601. doi: 10.1177/0883073813480243. Epub 2013 Mar 12.

PMID:
23481448
2.

Immunization with trivalent inactivated influenza vaccine in partially immunized toddlers.

Englund JA, Walter EB, Gbadebo A, Monto AS, Zhu Y, Neuzil KM.

Pediatrics. 2006 Sep;118(3):e579-85.

PMID:
16950949
3.

Influenza vaccine immunogenicity in 6- to 23-month-old children: are identical antigens necessary for priming?

Walter EB, Neuzil KM, Zhu Y, Fairchok MP, Gagliano ME, Monto AS, Englund JA.

Pediatrics. 2006 Sep;118(3):e570-8.

PMID:
16950948
4.

Improved antibody responses in infants less than 1 year old using intradermal influenza vaccination.

Sugimura T, Ito Y, Tananari Y, Ozaki Y, Maeno Y, Yamaoka T, Kudo Y.

Vaccine. 2008 May 23;26(22):2700-5. doi: 10.1016/j.vaccine.2008.03.016. Epub 2008 Mar 31.

PMID:
18436353
5.

Effect of prednisone on response to influenza virus vaccine in asthmatic children.

Fairchok MP, Trementozzi DP, Carter PS, Regnery HL, Carter ER.

Arch Pediatr Adolesc Med. 1998 Dec;152(12):1191-5.

PMID:
9856428
6.

Comparison of immunogenicity and tolerability of a virosome-adjuvanted and a split influenza vaccine in children.

Kanra G, Marchisio P, Feiterna-Sperling C, Gaedicke G, Lazar H, Durrer P, K├╝rsteiner O, Herzog C, Kara A, Principi N.

Pediatr Infect Dis J. 2004 Apr;23(4):300-6. Erratum in: Pediatr Infect Dis J. 2004 Jun;23(6):503.

PMID:
15071282
7.

Reactogenicity and immunogenicity of an inactivated influenza vaccine administered by intramuscular or subcutaneous injection in elderly adults.

Cook IF, Barr I, Hartel G, Pond D, Hampson AW.

Vaccine. 2006 Mar 20;24(13):2395-402. Epub 2005 Dec 13.

PMID:
16406171
8.

Dose sparing with intradermal injection of influenza vaccine.

Kenney RT, Frech SA, Muenz LR, Villar CP, Glenn GM.

N Engl J Med. 2004 Nov 25;351(22):2295-301. Epub 2004 Nov 3.

9.

Immunogenicity and safety of intradermal influenza vaccination in healthy older adults.

Chi RC, Rock MT, Neuzil KM.

Clin Infect Dis. 2010 May 15;50(10):1331-8. doi: 10.1086/652144.

PMID:
20377407
10.

Safety and immunogenicity of 2010-2011 H1N12009-containing trivalent inactivated influenza vaccine in children 12-59 months of age previously given AS03-adjuvanted H1N12009 pandemic vaccine: a PHAC/CIHR Influenza Research Network (PCIRN) study.

Langley JM, Scheifele DW, Quach C, Vanderkooi OG, Ward B, McNeil S, Dobson S, Kellner JD, Kuhn S, Kollman T, MacKinnon-Cameron D, Smith B, Li Y, Halperin SA.

Vaccine. 2012 May 14;30(23):3389-94. doi: 10.1016/j.vaccine.2012.03.046. Epub 2012 Mar 30.

PMID:
22469860
11.

Intanza(®) 15 mcg intradermal influenza vaccine elicits cross-reactive antibody responses against heterologous A(H3N2) influenza viruses.

Ansaldi F, Canepa P, Ceravolo A, Valle L, de Florentiis D, Oomen R, Vogel FR, Denis M, Samson SI, Icardi G.

Vaccine. 2012 Apr 16;30(18):2908-13. doi: 10.1016/j.vaccine.2012.02.003. Epub 2012 Feb 15.

PMID:
22342501
12.

Immunogenicity and safety of intradermal influenza immunization at a reduced dose in healthy children.

Chiu SS, Peiris JS, Chan KH, Wong WH, Lau YL.

Pediatrics. 2007 Jun;119(6):1076-82.

PMID:
17545373
13.

Half- vs full-dose trivalent inactivated influenza vaccine (2004-2005): age, dose, and sex effects on immune responses.

Engler RJ, Nelson MR, Klote MM, VanRaden MJ, Huang CY, Cox NJ, Klimov A, Keitel WA, Nichol KL, Carr WW, Treanor JJ; Walter Reed Health Care System Influenza Vaccine Consortium.

Arch Intern Med. 2008 Dec 8;168(22):2405-14. doi: 10.1001/archinternmed.2008.513.

PMID:
19064822
14.

Immunogenicity and reactogenicity of 1 versus 2 doses of trivalent inactivated influenza vaccine in vaccine-naive 5-8-year-old children.

Neuzil KM, Jackson LA, Nelson J, Klimov A, Cox N, Bridges CB, Dunn J, DeStefano F, Shay D.

J Infect Dis. 2006 Oct 15;194(8):1032-9. Epub 2006 Sep 11.

PMID:
16991077
15.

Hemagglutination inhibition antibody titers as a correlate of protection for inactivated influenza vaccines in children.

Black S, Nicolay U, Vesikari T, Knuf M, Del Giudice G, Della Cioppa G, Tsai T, Clemens R, Rappuoli R.

Pediatr Infect Dis J. 2011 Dec;30(12):1081-5. doi: 10.1097/INF.0b013e3182367662. Erratum in: Pediatr Infect Dis J. 2012 May;31(5):537.

PMID:
21983214
16.

Immunogenicity of a monovalent pandemic influenza A H1N1 virus vaccine with or without prior seasonal influenza vaccine administration.

Igari H, Watanabe A, Segawa S, Suzuki A, Watanabe M, Sakurai T, Watanabe M, Tatsumi K, Nakayama M, Suzuki K, Sato T.

Clin Vaccine Immunol. 2012 Oct;19(10):1690-2. Epub 2012 Aug 1.

17.

Prospective, randomized, placebo-controlled evaluation of the safety and immunogenicity of three lots of intranasal trivalent influenza vaccine among young children.

Zangwill KM, Droge J, Mendelman P, Marcy SM, Partridge S, Chiu CY, Jing J, Chang SJ, Cho I, Ward JI.

Pediatr Infect Dis J. 2001 Aug;20(8):740-6.

PMID:
11734734
18.

A randomized controlled trial of cold-adapted and inactivated vaccines for the prevention of influenza A disease.

Edwards KM, Dupont WD, Westrich MK, Plummer WD Jr, Palmer PS, Wright PF.

J Infect Dis. 1994 Jan;169(1):68-76.

PMID:
8277200
19.

Serum antibody responses after intradermal vaccination against influenza.

Belshe RB, Newman FK, Cannon J, Duane C, Treanor J, Van Hoecke C, Howe BJ, Dubin G.

N Engl J Med. 2004 Nov 25;351(22):2286-94. Epub 2004 Nov 3.

20.

Safety and immunogenicity of a live-attenuated influenza vaccine blended and filled at two manufacturing facilities.

Nolan T, Lee MS, Cordova JM, Cho I, Walker RE, August MJ, Larson S, Coelingh KL, Mendelman PM.

Vaccine. 2003 Mar 7;21(11-12):1224-31.

PMID:
12559802

Supplemental Content

Support Center